Last 12 months
Inside the activity.
1 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2021 Filed Jul 14, 2021 01:22 UTC |
Tutewohl SteveChief Operating Officer
|
SaleClass A Common Stock | 1,808 | $23.00 | $41,584.00 |
DisclosureSEC source: 0001628908-21-000098 · wf-form4_162622569628328.xml · nonDerivative · entry 4 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 09, 2021 Filed Jul 14, 2021 01:22 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock | 1,808 | $13.95 | $25,221.60 |
DisclosureSEC source: 0001628908-21-000098 · wf-form4_162622569628328.xml · nonDerivative · entry 3 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 09, 2021 Filed Jul 14, 2021 01:22 UTC |
Tutewohl SteveChief Operating Officer
|
SaleClass A Common Stock | 10,576 | $22.52 | $238,171.52 |
DisclosureSEC source: 0001628908-21-000098 · wf-form4_162622569628328.xml · nonDerivative · entry 2 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.25 to $22.95, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 09, 2021 Filed Jul 14, 2021 01:22 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock | 10,576 | $13.29 | $140,555.04 |
DisclosureSEC source: 0001628908-21-000098 · wf-form4_162622569628328.xml · nonDerivative · entry 1 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:59 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 200 | $0.00 Strike: $13.29 | $0.00 |
DisclosureSEC source: 0001628908-21-000096 · wf-form4_162612357619668.xml · derivative · entry 3 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,352 Underlying: Class A Common Stock · 200 shares Expires 2029-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F3 · derivative.exercise_date: The Class A Common Stock Options exercised vested on March 1, 2020. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:59 UTC |
Tutewohl SteveChief Operating Officer
|
SaleClass A Common Stock | 200 | $22.00 | $4,400.00 |
DisclosureSEC source: 0001628908-21-000096 · wf-form4_162612357619668.xml · nonDerivative · entry 2 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:59 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock | 200 | $13.29 | $2,658.00 |
DisclosureSEC source: 0001628908-21-000096 · wf-form4_162612357619668.xml · nonDerivative · entry 1 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:37 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 9,352 | $0.00 Strike: $7.83 | $0.00 |
DisclosureSEC source: 0001628908-21-000094 · wf-form4_162525821927146.xml · derivative · entry 3 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,702 Underlying: Class A Common Stock · 9,352 shares Expires 2029-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F4 · derivative.exercise_date: The Class A Common Stock Options exercised vested on July 1, 2021. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:37 UTC |
Tutewohl SteveChief Operating Officer
|
SaleClass A Common Stock | 9,352 | $21.05 | $196,859.60 |
DisclosureSEC source: 0001628908-21-000094 · wf-form4_162525821927146.xml · nonDerivative · entry 2 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $ 20.97 to $21.31, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:37 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock | 9,352 | $7.83 | $73,226.16 |
DisclosureSEC source: 0001628908-21-000094 · wf-form4_162525821927146.xml · nonDerivative · entry 1 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 29, 2021 Filed Feb 14, 2022 17:16 UTC |
WILLIAMS FRANK JDirector
|
GiftClass A Common Stock | 66,064 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-22-000014 · wf-form5_164487696413052.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 66,064 F1 · ownership.nature: On June 29, 2021 66,064 shares were transferred from the Williams 2019 GRAT to the Frank Williams Irrevocable Trust. Read SEC document |
| June 29, 2021 Filed Feb 14, 2022 17:16 UTC |
WILLIAMS FRANK JDirector
|
GiftClass A Common Stock | 66,064 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-22-000014 · wf-form5_164487696413052.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · ownership.nature: On June 29, 2021 66,064 shares were transferred from the Williams 2019 GRAT to the Frank Williams Irrevocable Trust. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:58 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-21-000092 · wf-form4_162430911080741.xml · derivative · entry 5 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 716,560 Underlying: Class A Common Stock · 10,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F6 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:58 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 10,000 | $19.70 | $197,000.00 |
DisclosureSEC source: 0001628908-21-000092 · wf-form4_162430911080741.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 648,294 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.461 to $19.9099, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:58 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock | 10,000 | $3.84 | $38,400.00 |
DisclosureSEC source: 0001628908-21-000092 · wf-form4_162430911080741.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:58 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 10,000 | $19.70 | $197,000.00 |
DisclosureSEC source: 0001628908-21-000092 · wf-form4_162430911080741.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 648,294 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.53 to $19.91, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 21:09 UTC |
Scott CherylDirector
|
SaleClass A Common Stock | 6,405 | $19.39 | $124,192.95 |
DisclosureSEC source: 0001628908-21-000090 · wf-form4_162379131337267.xml · nonDerivative · entry 1 Scott Cheryl · CIK 0001656979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,640 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.22 to $19.60, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:45 UTC |
KECK KIMDirector
|
GrantClass A Common Stock | 7,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000081 · wf-form4_162370712373219.xml · nonDerivative · entry 1 KECK KIM · CIK 0001818332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,660 F1 · security: Represents restricted stock units granted to Ms. Keck pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 10, 2022 and the date of the company's 2022 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 17:44 UTC |
D'Amato MichaelDirector
|
GrantClass A Common Stock | 7,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000080 · wf-form4_162370702373481.xml · nonDerivative · entry 1 D'Amato Michael · CIK 0001672282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,455 F1 · security: Represents restricted stock units granted to Mr D'Amato pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 10, 2022 and the date of the company's 2022 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 17:38 UTC |
Holder DianeDirector
|
GrantClass A Common Stock | 7,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000078 · wf-form4_162370667545789.xml · nonDerivative · entry 1 Holder Diane · CIK 0001642976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,527 F1 · security: Represents restricted stock units granted to Ms. Holder pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 10, 2022 and the date of the company's 2022 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 17:33 UTC |
Farner DavidDirector
|
GrantClass A Common Stock | 7,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000076 · wf-form4_162370637225570.xml · nonDerivative · entry 1 Farner David · CIK 0001642786 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,527 F1 · security: Represents restricted stock units granted to Mr. Farner pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 10, 2022 and the date of the company's 2022 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:39 UTC |
GRUA PETER JDirector
|
GrantClass A Common Stock | 7,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000079 · wf-form4_162370676653960.xml · nonDerivative · entry 1 GRUA PETER J · CIK 0001242813 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,306 F1 · security: Represents restricted stock units granted to Mr. Grua pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 10, 2022 and the date of the company's 2022 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 19:41 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
GrantClass A Common Stock | 7,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000084 · wf-form4_162371407450832.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658,294 F1 · security: Represents restricted stock units granted to Mr. Williams pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 10, 2022 and the date of the company's 2022 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:46 UTC |
Barbarosh Craig A.Director
|
GrantClass A Common Stock | 7,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000082 · wf-form4_162370720309393.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,634 F1 · security: Represents restricted stock units granted to Mr. Barbarosh pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 10, 2022 and the date of the company's 2022 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 17:31 UTC |
DUFFY MARY BRIDGETDirector
|
GrantClass A Common Stock | 7,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000075 · wf-form4_162370627911780.xml · nonDerivative · entry 1 DUFFY MARY BRIDGET · CIK 0001570881 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,386 F1 · security: Represents restricted stock units granted to Ms. Duffy pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 10, 2022 and the date of the company's 2022 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:35 UTC |
Scott CherylDirector
|
GrantClass A Common Stock | 7,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000077 · wf-form4_162370653836039.xml · nonDerivative · entry 1 Scott Cheryl · CIK 0001656979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,045 F1 · security: Represents restricted stock units granted to Ms. Scott pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 10, 2022 and the date of the company's 2022 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document |
| June 03, 2021 Filed Feb 14, 2022 22:24 UTC |
Scott CherylDirector
|
GiftClass A Common Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-22-000016 · wf-form5_164487746124173.xml · nonDerivative · entry 1 Scott Cheryl · CIK 0001656979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,640 F1 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:15 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628280-21-010735 · wf-form4_162146972771096.xml · derivative · entry 5 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 726,560 Underlying: Class A Common Stock · 10,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F6 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:15 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 10,000 | $19.65 | $196,500.00 |
DisclosureSEC source: 0001628280-21-010735 · wf-form4_162146972771096.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,509 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.41 to $19.82, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:15 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 10,000 | $19.81 | $198,100.00 |
DisclosureSEC source: 0001628280-21-010735 · wf-form4_162146972771096.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 660,509 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.65 to $19.90, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:15 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock | 10,000 | $3.84 | $38,400.00 |
DisclosureSEC source: 0001628280-21-010735 · wf-form4_162146972771096.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 04, 2021 Filed May 6, 2021 22:03 UTC |
Weinberg JonathanGeneral Counsel
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-21-000056 · wf-form4_162033855200883.xml · derivative · entry 3 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,431 Underlying: Class A Common Stock · 20,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021. F4 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2017 and February 1, 2018. Read SEC document |
| May 04, 2021 Filed May 6, 2021 22:03 UTC |
Weinberg JonathanGeneral Counsel
|
SaleClass A Common Stock | 20,000 | $21.37 | $427,400.00 |
DisclosureSEC source: 0001628908-21-000056 · wf-form4_162033855200883.xml · nonDerivative · entry 2 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,775 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.18 to $21.58, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 04, 2021 Filed May 6, 2021 22:03 UTC |
Weinberg JonathanGeneral Counsel
|
Exercise / conversionClass A Common Stock | 20,000 | $3.84 | $76,800.00 |
DisclosureSEC source: 0001628908-21-000056 · wf-form4_162033855200883.xml · nonDerivative · entry 1 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:01 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 9,352 | $0.00 Strike: $7.83 | $0.00 |
DisclosureSEC source: 0001628908-21-000051 · wf-form4_162025209202092.xml · derivative · entry 4 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,054 Underlying: Class A Common Stock · 9,352 shares Expires 2029-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F5 · derivative.exercise_date: The Class A Common Stock Options exercised vested on July 1, 2020. Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:01 UTC |
Tutewohl SteveChief Operating Officer
|
SaleClass A Common Stock | 9,352 | $21.49 | $200,974.48 |
DisclosureSEC source: 0001628908-21-000051 · wf-form4_162025209202092.xml · nonDerivative · entry 3 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,103 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.36 to $21.73, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:01 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock | 9,352 | $7.83 | $73,226.16 |
DisclosureSEC source: 0001628908-21-000051 · wf-form4_162025209202092.xml · nonDerivative · entry 2 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:01 UTC |
Tutewohl SteveChief Operating Officer
|
SaleClass A Common Stock | 9,943 | $21.48 | $213,575.64 |
DisclosureSEC source: 0001628908-21-000051 · wf-form4_162025209202092.xml · nonDerivative · entry 1 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,103 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.32 to $21.73, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:54 UTC |
Shams AammaadController/Prin. Acct. Officer
|
GrantClass A Common Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000036 · wf-form4_161482283976638.xml · nonDerivative · entry 1 Shams Aammaad · CIK 0001815354 · Controller/Prin. Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · security: Represents restricted stock units granted to Mr. Shams pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 25% annually beginning March 1, 2022. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:42 UTC |
Weinberg JonathanGeneral Counsel
|
GrantClass A Common Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000030 · wf-form4_161482215883136.xml · nonDerivative · entry 1 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,775 F1 · security: Represents restricted stock units granted to Mr. Weinberg pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 25% annually beginning March 1, 2022. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:49 UTC |
Tutewohl SteveChief Operating Officer
|
GrantClass A Common Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000034 · wf-form4_161482253003982.xml · nonDerivative · entry 1 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,046 F1 · security: Includes restricted stock units granted to Mr. Tutewohl pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 25% annually beginning March 1, 2022. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 3s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:46 UTC |
Johnson John PaulChief Financial Officer
|
GrantClass A Common Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000032 · wf-form4_161482238021079.xml · nonDerivative · entry 1 Johnson John Paul · CIK 0001782040 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,921 F1 · security: Includes restricted stock units granted to Mr. Johnson pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 25% annually beginning March 1, 2022. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:39 UTC |
Blackley SethDirector · Chief Executive Officer
|
GrantClass A Common Stock | 46,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000028 · wf-form4_161482197473209.xml · nonDerivative · entry 1 Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,842 F1 · security: Represents restricted stock units granted to Mr. Blackley pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation plan. F2 · shares: Securities vest at a rate of 25% annually beginning March 1, 2022. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:18 UTC |
KECK KIMDirector
|
GrantClass A Common Stock | 2,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000014 · wf-form4_161238707099274.xml · nonDerivative · entry 1 KECK KIM · CIK 0001818332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,875 F1 · security: Represents restricted stock units granted to Ms. Keck pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of February 1, 2022 and the date of the company's 2021 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:56 UTC |
Barbarosh Craig A.Director
|
GrantClass A Common Stock | 3,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000002 · wf-form4_160997736594444.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,849 F1 · security: Represents restricted stock units granted to Mr. Barbarosh pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of January 4, 2022 and the date of the Company's 2021 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document |
| August 05, 2020 Filed Aug 8, 2020 00:51 UTC |
Weinberg JonathanGeneral Counsel
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001642833-20-000003 · wf-form4_159684779432926.xml · derivative · entry 3 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,431 Underlying: Class A Common Stock · 10,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2020. F4 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2017. Read SEC document |
| August 05, 2020 Filed Aug 8, 2020 00:51 UTC |
Weinberg JonathanGeneral Counsel
|
SaleClass A Common Stock | 10,000 | $13.01 | $130,100.00 |
DisclosureSEC source: 0001642833-20-000003 · wf-form4_159684779432926.xml · nonDerivative · entry 2 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,775 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.000 to $13.015, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 05, 2020 Filed Aug 8, 2020 00:51 UTC |
Weinberg JonathanGeneral Counsel
|
Exercise / conversionClass A Common Stock | 10,000 | $3.84 | $38,400.00 |
DisclosureSEC source: 0001642833-20-000003 · wf-form4_159684779432926.xml · nonDerivative · entry 1 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2020. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:27 UTC |
D'Amato MichaelDirector
|
GrantClass A Common Stock | 18,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-20-000074 · wf-form4_159191084674915.xml · nonDerivative · entry 1 D'Amato Michael · CIK 0001672282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,670 F1 · security: Represents restricted stock units granted to Mr. D'Amato pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 9, 2021 and the date of the company's 2021 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:32 UTC |
Holder DianeDirector
|
GrantClass A Common Stock | 18,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-20-000078 · wf-form4_159191114331425.xml · nonDerivative · entry 1 Holder Diane · CIK 0001642976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,742 F1 · security: Represents restricted stock units granted to Ms. Holder pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 9, 2021 and the date of the company's 2021 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.